GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
TIGIT
Target has curated data in GtoImmuPdb
Target id: 2941
Nomenclature: TIGIT
Family: Other immune checkpoint proteins, Immunoglobulin like domain containing proteins
Annotation status:
Awaiting annotation
» Email us
Contents:
- Quaternary Structure
- Gene and Protein Information
- Previous and Unofficial Names
- Database Links
- Selected 3D Structures
- Associated Proteins
- Functional Characteristics
- Natural/Endogenous Ligands
- Rank order lists
- Activators
- Inhibitors
- Gating Inhibitors
- Agonists
- Antagonists
- Channel Blockers
- Allosteric Modulators
- Antibodies
- Other Binding Ligands
- Whole Organism Assay Data
- Large-scale Ligand Screening Data
- Immunopharmacology Comments
- Immuno Cell Type Associations
- Immuno Process Associations
- Immuno Disease Associations
- Malaria Pharmacology Comments
- Tissue Distribution
- Expression Datasets
- Functional Assays
- Physiological Functions
- Physiological Consequences of Altering Gene Expression
- Xenobiotics Influencing Gene Expression
- Phenotypes, Alleles and Disease Models
- Clinically-Relevant Mutations and Pathophysiology
- Gene Expression and Pathophysiology
- Biologically Significant Variants
- General Comments
- Available Assays
- References
- Contributors
- How to cite this page
Gene and Protein Information  |
||||||
| Species | TM | AA | Chromosomal Location | Gene Symbol | Gene Name | Reference |
| Human | 1 | 244 | 3q13.31 | TIGIT | T cell immunoreceptor with Ig and ITIM domains | 5 |
| Mouse | 1 | 249 | 16 B4 | Tigit | T cell immunoreceptor with Ig and ITIM domains | |
| Rat | - | - | 11q21 | Tigit | T cell immunoreceptor with Ig and ITIM domains | |
| Previous and Unofficial Names |
|
| T-cell immunoreceptor with Ig and ITIM domains | V-set and immunoglobulin domain containing 9 | V-set and transmembrane domain containing 3 | VSIG9 | VSTM3 | WUCAM [2] | |
| Database Links |
|
| Alphafold | Q495A1 (Hs), P86176 (Mm) |
| CATH/Gene3D | 2.60.40.10 |
| ChEMBL Target | CHEMBL4630878 (Hs) |
| Ensembl Gene | ENSG00000181847 (Hs), ENSMUSG00000071552 (Mm), ENSRNOG00000056574 (Rn) |
| Entrez Gene | 201633 (Hs), 100043314 (Mm), 363784 (Rn) |
| Human Protein Atlas | ENSG00000181847 (Hs) |
| KEGG Gene | hsa:201633 (Hs), mmu:100043314 (Mm), rno:363784 (Rn) |
| OMIM | 612859 (Hs) |
| Pharos | Q495A1 (Hs) |
| RefSeq Nucleotide | NM_173799 (Hs), NM_001146325 (Mm) |
| RefSeq Protein | NP_776160 (Hs), NP_001139797 (Mm) |
| UniProtKB | Q495A1 (Hs), P86176 (Mm) |
| Wikipedia | TIGIT (Hs) |
Download all structure-activity data for this target as a CSV file 
| Antibodies | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Key to terms and symbols | Click column headers to sort | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Immunopharmacology Comments |
| TIGIT is now considered as an alternate inhibitory immune checkpoint protein which may have potential immunotherapeutic potential, particularly in conditions refractory to more established PD-1 checkpoint inhibition. Given its presence on T cells and NK cells, TIGIT offers an intervention point for targeting both the adaptive and innate arms of the immune system. Clinical development of anti-TIGIT monoclonal antibodies is in preliminary stages. Combination therapies with existing immune checkpoint inhibitors are considered particularly promising. MTIG7192A (NCT02794571; ± anti-PD-L1 atezolizumab) and BMS-986207 (NCT02913313; ± anti-PD-1 nivolumab) are two early phase potential immuno-oncology mAbs that prevent TIGIT-PVR interaction. OncoMed, Arcus Biosciences and Merck also have anti-TIGIT antibodies in their immuno-oncology pipelines (OMP-313M32/etigilimab, AB154/domvanalimab, and MK-7684 respectively) [4]. |
| Cell Type Associations | ||||||||
|
||||||||
|
||||||||
|
| General Comments |
|
TIGIT was originally identified as a high affinity binding partner of the poliovirus receptor (PVR; P15151). TIGIT-PVR interaction promotes the generation of mature immunoregulatory dendritic cells and leads to suppression of T cell activation. The TIGIT protein contains an immunoglobulin (Ig)-like domain that resembles the antibody variable domain, that has been coined the 'V-set domain'. The genes for all human V-set domain containing proteins are listed in HGNC gene group 590. |
References
1. Arcus Biosciences. ANTI-TIGIT - DOMVANALIMAB. Accessed on 09/07/2025. Modified on 09/07/2025. arcusbio.com, https://arcusbio.com/our-science/clinical-candidates/domvanalimab/
2. Boles KS, Vermi W, Facchetti F, Fuchs A, Wilson TJ, Diacovo TG, Cella M, Colonna M. (2009) A novel molecular interaction for the adhesion of follicular CD4 T cells to follicular DC. Eur J Immunol, 39 (3): 695-703. [PMID:19197944]
3. Mariotti FR, Quatrini L, Munari E, Vacca P, Moretta L. (2019) Innate Lymphoid Cells: Expression of PD-1 and Other Checkpoints in Normal and Pathological Conditions. Front Immunol, 10: 910. [PMID:31105707]
4. Rousseau A, Parisi C, Barlesi F. (2023) Anti-TIGIT therapies for solid tumors: a systematic review. ESMO Open, 8 (2): 101184. [PMID:36933320]
5. Yu X, Harden K, Gonzalez LC, Francesco M, Chiang E, Irving B, Tom I, Ivelja S, Refino CJ, Clark H et al.. (2009) The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat Immunol, 10 (1): 48-57. [PMID:19011627]
How to cite this page
Other immune checkpoint proteins: TIGIT. Last modified on 09/07/2025. Accessed on 12/09/2025. IUPHAR/BPS Guide to PHARMACOLOGY, https://www.guidetoimmunopharmacology.org/GRAC/ObjectDisplayForward?objectId=2941.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License